These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 8087983)

  • 41. Aldose and aldehyde reductases in human tissues.
    Srivastava SK; Ansari NH; Hair GA; Das B
    Biochim Biophys Acta; 1984 Aug; 800(3):220-7. PubMed ID: 6432055
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Establishment of monoclonal antibodies against human erythrocyte NADH-cytochrome b5 reductase.
    Lan F; Tang Y; Huang C; Zhu Z
    Hybridoma; 1996 Aug; 15(4):295-8. PubMed ID: 8880217
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Purification of aldose reductase from human placenta and stabilization of the inhibitor binding site.
    Vander Jagt DL; Stangebye LA; Hunsaker LA; Eaton RP; Sibbitt WL
    Biochem Pharmacol; 1988 Mar; 37(6):1051-6. PubMed ID: 3128293
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Thermal stress and diabetic complications.
    Ohtsuka Y; Yabunaka N; Watanabe I; Noro H; Fujisawa H; Agishi Y
    Int J Biometeorol; 1995 Jan; 38(2):57-9. PubMed ID: 7698855
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Kinetics and molecular docking studies of an anti-diabetic complication inhibitor fucosterol from edible brown algae Eisenia bicyclis and Ecklonia stolonifera.
    Jung HA; Islam MN; Lee CM; Oh SH; Lee S; Jung JH; Choi JS
    Chem Biol Interact; 2013 Oct; 206(1):55-62. PubMed ID: 23994501
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The pharmacology of aldose reductase inhibitors.
    Kador PF; Robison WG; Kinoshita JH
    Annu Rev Pharmacol Toxicol; 1985; 25():691-714. PubMed ID: 3923907
    [No Abstract]   [Full Text] [Related]  

  • 47. Discoveries in research on diabetic keratopathy.
    Cisarik-Fredenburg P
    Optometry; 2001 Nov; 72(11):691-704. PubMed ID: 12363257
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Aldose reductase in the diabetic eye. XLIII Edward Jackson memorial lecture.
    Kinoshita JH
    Am J Ophthalmol; 1986 Dec; 102(6):685-92. PubMed ID: 3098107
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Selectivity determinants of the aldose and aldehyde reductase inhibitor-binding sites.
    El-Kabbani O; Podjarny A
    Cell Mol Life Sci; 2007 Aug; 64(15):1970-8. PubMed ID: 17497245
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of aldose reductase inhibitor (Ponalrestat) on erythrocyte Na,K-ATPase activity in non-insulin-dependent diabetic patients with polyneuropathy.
    Umeda F; Noda K; Hashimoto T; Yamashita T; Nawata H
    Diabetes Res; 1989 Nov; 12(3):125-9. PubMed ID: 2561396
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Enzyme immunoassay for intact human insulin in serum or plasma.
    Andersen L; Dinesen B; Jørgensen PN; Poulsen F; Røder ME
    Clin Chem; 1993 Apr; 39(4):578-82. PubMed ID: 8472350
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Aldose reductase inhibitors and diabetic kidney disease.
    Oates PJ
    Curr Opin Investig Drugs; 2010 Apr; 11(4):402-17. PubMed ID: 20336588
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Purification and characterization of the recombinant human aldose reductase expressed in baculovirus system.
    Nishimura C; Yamaoka T; Mizutani M; Yamashita K; Akera T; Tanimoto T
    Biochim Biophys Acta; 1991 Jun; 1078(2):171-8. PubMed ID: 1905957
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Two-site enzyme immunoassay of cholesteryl ester transfer protein with monoclonal and oligoclonal antibodies.
    Mezdour H; Kora I; Parra HJ; Tartar A; Marcel YL; Fruchart JC
    Clin Chem; 1994 Apr; 40(4):593-7. PubMed ID: 7511997
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Kinetic characteristics of ZENECA ZD5522, a potent inhibitor of human and bovine lens aldose reductase.
    Cook PN; Ward WH; Petrash JM; Mirrlees DJ; Sennitt CM; Carey F; Preston J; Brittain DR; Tuffin DP; Howe R
    Biochem Pharmacol; 1995 Apr; 49(8):1043-9. PubMed ID: 7748183
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Erythrocyte aldose reductase correlates with erectile dysfunction in diabetic patients.
    Naya Y; Soh J; Ochiai A; Mizutani Y; Kawauchi A; Fujito A; Ushijima S; Ono T; Iwamoto N; Aoki T; Imada N; Nakamura N; Yabe-Nishimura C; Miki T
    Int J Impot Res; 2002 Aug; 14(4):213-6. PubMed ID: 12152109
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Protective effect of Tephrosia purpurea in diabetic cataract through aldose reductase inhibitory activity.
    Bhadada SV; Vyas VK; Goyal RK
    Biomed Pharmacother; 2016 Oct; 83():221-228. PubMed ID: 27372406
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Aldose reductase inhibition of a saponin-rich fraction and new furostanol saponin derivatives from Balanites aegyptiaca.
    Abdel Motaal A; El-Askary H; Crockett S; Kunert O; Sakr B; Shaker S; Grigore A; Albulescu R; Bauer R
    Phytomedicine; 2015 Aug; 22(9):829-36. PubMed ID: 26220630
    [TBL] [Abstract][Full Text] [Related]  

  • 59. High glucose levels induce inhibition of Na,K-ATPase via stimulation of aldose reductase, formation of microtubules and formation of an acetylated tubulin/Na,K-ATPase complex.
    Rivelli JF; Amaiden MR; Monesterolo NE; Previtali G; Santander VS; Fernandez A; Arce CA; Casale CH
    Int J Biochem Cell Biol; 2012 Aug; 44(8):1203-13. PubMed ID: 22565168
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Potential use of aldose reductase inhibitors to prevent diabetic complications.
    Zenon GJ; Abobo CV; Carter BL; Ball DW
    Clin Pharm; 1990 Jun; 9(6):446-57. PubMed ID: 2114249
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.